Contrasting Impax Laboratories (IPXL) and Its Competitors

Impax Laboratories (NASDAQ: IPXL) is one of 114 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Impax Laboratories to related companies based on the strength of its dividends, risk, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Insider & Institutional Ownership

86.3% of Impax Laboratories shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.2% of Impax Laboratories shares are owned by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Impax Laboratories has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Impax Laboratories’ competitors have a beta of 0.88, meaning that their average share price is 12% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Impax Laboratories and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Impax Laboratories 1 9 5 0 2.27
Impax Laboratories Competitors 804 3576 6170 156 2.53

Impax Laboratories presently has a consensus price target of $19.67, suggesting a potential downside of 6.35%. As a group, “Pharmaceuticals” companies have a potential upside of 22.12%. Given Impax Laboratories’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Impax Laboratories has less favorable growth aspects than its competitors.

Profitability

This table compares Impax Laboratories and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Impax Laboratories -71.08% 9.05% 3.20%
Impax Laboratories Competitors -3,036.76% -54.42% -9.10%

Valuation and Earnings

This table compares Impax Laboratories and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Impax Laboratories $812.82 million $144.42 million -2.60
Impax Laboratories Competitors $8.02 billion $2.61 billion 0.18

Impax Laboratories’ competitors have higher revenue and earnings than Impax Laboratories. Impax Laboratories is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Impax Laboratories competitors beat Impax Laboratories on 7 of the 13 factors compared.

Impax Laboratories Company Profile

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply